JPH11507218A5 - - Google Patents

Info

Publication number
JPH11507218A5
JPH11507218A5 JP1997501658A JP50165897A JPH11507218A5 JP H11507218 A5 JPH11507218 A5 JP H11507218A5 JP 1997501658 A JP1997501658 A JP 1997501658A JP 50165897 A JP50165897 A JP 50165897A JP H11507218 A5 JPH11507218 A5 JP H11507218A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997501658A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11507218A (ja
Filing date
Publication date
Priority claimed from US08/474,497 external-priority patent/US5994315A/en
Application filed filed Critical
Publication of JPH11507218A publication Critical patent/JPH11507218A/ja
Publication of JPH11507218A5 publication Critical patent/JPH11507218A5/ja
Ceased legal-status Critical Current

Links

JP9501658A 1995-06-07 1996-06-06 アンチセンスオリゴヌクレオチドを用いる肺疾患の治療方法 Ceased JPH11507218A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/474,497 1995-06-07
US08/474,497 US5994315A (en) 1995-06-07 1995-06-07 Low adenosine agent, composition, kit and method for treatment of airway disease
PCT/US1996/009306 WO1996040162A1 (en) 1995-06-07 1996-06-06 Method of treatment for lung diseases using antisense oligonucleotides

Publications (2)

Publication Number Publication Date
JPH11507218A JPH11507218A (ja) 1999-06-29
JPH11507218A5 true JPH11507218A5 (enExample) 2004-07-22

Family

ID=23883783

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9501658A Ceased JPH11507218A (ja) 1995-06-07 1996-06-06 アンチセンスオリゴヌクレオチドを用いる肺疾患の治療方法

Country Status (7)

Country Link
US (1) US5994315A (enExample)
EP (1) EP0831848A4 (enExample)
JP (1) JPH11507218A (enExample)
CN (1) CN1134260C (enExample)
AU (1) AU726468B2 (enExample)
CA (1) CA2223776C (enExample)
WO (1) WO1996040162A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US7034007B1 (en) 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
US6214806B1 (en) * 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
GB9718487D0 (en) * 1997-09-02 1997-11-05 Univ Sheffield Pulmonary hypertension
KR20010030622A (ko) * 1997-09-17 2001-04-16 리차드 알. 이킨 다중 표적 하이브리드형성 핵산과 그들의 제조, 구성,제제, 키트 및 응용
US6046319A (en) * 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
AU1616499A (en) * 1997-12-01 1999-06-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chemokine variants and methods of use
US6121023A (en) * 1998-01-22 2000-09-19 Akzo Nobel N.V. Isothermal transcription based assay for the detection and quantification of the chemokine rantes
US6525185B1 (en) 1998-05-07 2003-02-25 Affymetrix, Inc. Polymorphisms associated with hypertension
ES2272069T3 (es) 1998-05-22 2007-04-16 Ottawa Health Research Institute Metodos y productos para inducir inmunidad en mucosas.
CA2316994A1 (en) * 1998-06-08 1999-12-16 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
US7244714B1 (en) * 1998-06-12 2007-07-17 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
AU5337499A (en) * 1998-08-03 2000-03-06 East Carolina University Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
US6080580A (en) * 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US6228642B1 (en) * 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
AU3512300A (en) * 1999-03-05 2000-09-21 Epigenesis Pharmaceuticals, Inc. Method for validating/invalidating target(s) and pathways
US6136603A (en) * 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
WO2000062736A2 (en) * 1999-04-06 2000-10-26 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
WO2000078946A2 (en) * 1999-06-17 2000-12-28 Eastern Virginia Medical School Treatment of viral influenza with antisense oligonucleotides
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
AU2002256359A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US20090247606A1 (en) * 2001-08-28 2009-10-01 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
FR2848573B1 (fr) * 2002-12-13 2005-04-08 Exonhit Therapeutics Sa Compositions et methodes pour la detection et le traitement de pathologies neurodegeneratives
AU2004231122B2 (en) 2003-04-15 2010-04-08 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
WO2006091841A2 (en) 2005-02-25 2006-08-31 Isis Pharmaceuticals, Inc. Compositions and their uses directed to il-4r alpha
WO2007068747A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
AU2007260236B2 (en) 2006-06-12 2013-05-16 Kuros Us Llc Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
JP5653899B2 (ja) 2008-03-17 2015-01-14 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 神経筋シナプスの維持および再生に関与するマイクロrnaの同定
US9399125B2 (en) 2013-02-13 2016-07-26 Becton, Dickinson And Company Needleless connector and access port disinfection cleaner and antimicrobial protection cap

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5245022A (en) * 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
GB2264948B (en) * 1992-03-13 1996-10-16 Merck & Co Inc Human adenosine receptors
WO1993020200A1 (en) * 1992-04-02 1993-10-14 Imperial Cancer Research Technology Limited Modified cells and method of treatment
US5320962A (en) * 1992-07-22 1994-06-14 Duke University DNA encoding the human A1 adenosine receptor
US5631237A (en) * 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation

Similar Documents

Publication Publication Date Title
JP2000500445A5 (enExample)
JP2000500033A5 (enExample)
JP2000500440A5 (enExample)
JP2000500327A5 (enExample)
JP2001503338A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JP2000500361A5 (enExample)
JP2000500115A5 (enExample)
JP2000500322A5 (enExample)
JP2000500485A5 (enExample)
JP2000500258A5 (enExample)
JP2000500342A5 (enExample)
JP2000500192A5 (enExample)
JP2000500112A5 (enExample)
JP2000500226A5 (enExample)
JP2000500051A5 (enExample)
JP2000500397A5 (enExample)
JP2000500407A5 (enExample)
JP2000500166A5 (enExample)
JP2000500125A5 (enExample)
JP2000500346A5 (enExample)
JP2000500044A5 (enExample)
JP2000500257A5 (enExample)
JP2000500090A5 (enExample)